Dr. Prasad, the FDA’s Grim Reaper
NegativeU.S News

The recent decision by the FDA to block a therapy for late-stage melanoma has raised serious concerns, as it could lead to the loss of many lives. This move has been criticized by experts, including Dr. Prasad, who argue that access to effective treatments is crucial for patients facing this aggressive cancer. The implications of this decision are significant, as it not only affects individual patients but also highlights broader issues within the healthcare system regarding the approval of life-saving therapies.
— Curated by the World Pulse Now AI Editorial System